Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG
SHANDONG has sixteen approved drugs.
There are five US patents protecting SHANDONG drugs. There are two tentative approvals on SHANDONG drugs.
There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and fifty-six supplementary protection certificates in thirteen countries.
Summary for Shandong
| International Patents: | 29 |
| US Patents: | 5 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 16 |
Drugs and US Patents for Shandong
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 202413-001 | Nov 23, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shandong | PIPERACILLIN AND TAZOBACTAM | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 204959-002 | Aug 10, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shandong Xinhua | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 211886-002 | Jan 25, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20150050598 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2012146052 | ⤷ Start Trial |
| Poland | 3566696 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shandong Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2059246 | C202430051 | Spain | ⤷ Start Trial | PRODUCT NAME: UNA COMBINACION DE (A) MACITENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y (B) TADALAFILO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1859; DATE OF AUTHORISATION: 20240927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1859; DATE OF FIRST AUTHORISATION IN EEA: 20240927 |
| 0287150 | 96C0038 | Belgium | ⤷ Start Trial | PRODUCT NAME: ROCURONIUMBROMIDE; NAT. REGISTRATION NO/DATE: 63 IS 9 F 12 19960709; FIRST REGISTRATION: NL RVG 16946 19940406 |
| 2059246 | 122024000070 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AUS (A) MACITENTAN ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND (B) TADALAFIL ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1859 20240927 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
